Clinical correlates and metabolic indicators of elevated fasting glucose in overweight/obese Chinese Han patients with first-episode and drug-naive major depressive disorder.
BMI
Chinese Han
fasting glucose
first-episode and drug-naïve major depressive disorder
overweight/obese
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2023
2023
Historique:
received:
19
11
2022
accepted:
03
03
2023
medline:
4
4
2023
entrez:
3
4
2023
pubmed:
4
4
2023
Statut:
epublish
Résumé
Overweight/obese major depressive disorder (MDD) patients have a high probability of developing glucose metabolism disorders; however, the results are inconsistent due to the confounding variables involved in the studies. The purpose of this study was to explore the prevalence and risk factors for elevated fasting glucose in Chinese Han patients with overweight/obese first-episode and drug naïve (FEDN) MDD. The study used a cross-sectional design and recruited 1718 FEDN MDD patients between the ages of 18 and 60 years. Socio-demographic information, anthropometric data, and biochemical parameters were collected. The 17-item Hamilton Assessment Scale for Depression (HAMD), the 14-item Hamilton Anxiety Scale (HAMA), and the Positive and Negative Syndrome Scale (PANSS) positive subscale were used to assess symptoms of all patients. MDD patients with elevated fasting glucose had higher TSH, TPOAb, TC, TG, LDL-C, systolic and diastolic blood pressure levels than those with normal fasting glucose. Logistic regression analysis showed that age, TSH, TgAb, TPOA, and TG were related factors for elevated fasting glucose, while TSH and combination all these five parameters had the potential to differentiate between patients with elevated fasting glucose and those with normal fasting glucose. Multifactorial regression analysis showed that TSH, TG, and LDL-C were independently associated with elevated fasting glucose. Our findings suggest a high prevalence of elevated fasting glucose in overweight/obese FEDN MDD patients. Several clinically relevant factors and metabolic parameters are associated with elevated fasting glucose in overweight/obese FEDN MDD patients. Due to the cross-sectional design, no causal relationship could be derived.
Sections du résumé
Background
Overweight/obese major depressive disorder (MDD) patients have a high probability of developing glucose metabolism disorders; however, the results are inconsistent due to the confounding variables involved in the studies. The purpose of this study was to explore the prevalence and risk factors for elevated fasting glucose in Chinese Han patients with overweight/obese first-episode and drug naïve (FEDN) MDD.
Methods
The study used a cross-sectional design and recruited 1718 FEDN MDD patients between the ages of 18 and 60 years. Socio-demographic information, anthropometric data, and biochemical parameters were collected. The 17-item Hamilton Assessment Scale for Depression (HAMD), the 14-item Hamilton Anxiety Scale (HAMA), and the Positive and Negative Syndrome Scale (PANSS) positive subscale were used to assess symptoms of all patients.
Results
MDD patients with elevated fasting glucose had higher TSH, TPOAb, TC, TG, LDL-C, systolic and diastolic blood pressure levels than those with normal fasting glucose. Logistic regression analysis showed that age, TSH, TgAb, TPOA, and TG were related factors for elevated fasting glucose, while TSH and combination all these five parameters had the potential to differentiate between patients with elevated fasting glucose and those with normal fasting glucose. Multifactorial regression analysis showed that TSH, TG, and LDL-C were independently associated with elevated fasting glucose.
Conclusion
Our findings suggest a high prevalence of elevated fasting glucose in overweight/obese FEDN MDD patients. Several clinically relevant factors and metabolic parameters are associated with elevated fasting glucose in overweight/obese FEDN MDD patients.
Limitation
Due to the cross-sectional design, no causal relationship could be derived.
Identifiants
pubmed: 37008928
doi: 10.3389/fendo.2023.1102670
pmc: PMC10057961
doi:
Substances chimiques
Glucose
IY9XDZ35W2
Cholesterol, LDL
0
Thyrotropin
9002-71-5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1102670Informations de copyright
Copyright © 2023 Gao, Deng, Cai, Zhang, Xiao and Zhang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Can J Psychiatry. 2006 Apr;51(5):274-80
pubmed: 16986816
J Diabetes. 2013 Dec;5(4):471-81
pubmed: 23489875
Psychiatr Clin North Am. 1996 Jun;19(2):179-200
pubmed: 8827185
J Pediatr Health Care. 2013 Mar-Apr;27(2):120-6
pubmed: 23414977
Indian J Psychol Med. 2017 Nov-Dec;39(6):766-769
pubmed: 29284809
Clin Pract Epidemiol Ment Health. 2013 Jul 12;9:136-41
pubmed: 23935696
Diabetologia. 2010 Dec;53(12):2480-6
pubmed: 20711716
Diabetologia. 2006 Dec;49(12):2874-7
pubmed: 17066302
World J Biol Psychiatry. 2021 Feb;22(2):128-138
pubmed: 32425087
Arch Gen Psychiatry. 2008 Dec;65(12):1386-93
pubmed: 19047525
Biomed Environ Sci. 2002 Mar;15(1):83-96
pubmed: 12046553
Psychoneuroendocrinology. 2019 Dec;110:104425
pubmed: 31542635
J Diabetes Complications. 2005 Mar-Apr;19(2):113-22
pubmed: 15745842
World Psychiatry. 2011 Feb;10(1):52-77
pubmed: 21379357
Psychosom Med. 2005 May-Jun;67(3):407-12
pubmed: 15911903
J Neuroendocrinol. 2017 Aug;29(8):
pubmed: 28718206
Prev Med. 2013 Mar;56(3-4):225-30
pubmed: 23295173
Diabetes Care. 2009 Jan;32 Suppl 1:S13-61
pubmed: 19118286
Int J Stroke. 2013 Jan;8(1):3-4
pubmed: 23280261
Psychiatriki. 2011 Oct-Dec;22(4):307-13
pubmed: 22271843
Front Neurosci. 2013 Oct 07;7:177
pubmed: 24109426
Biol Psychiatry. 2004 Jan 1;55(1):1-9
pubmed: 14706419
Am J Cardiol. 2002 Dec 15;90(12):1279-83
pubmed: 12480034
Biomed Environ Sci. 2013 Jan;26(1):1-12
pubmed: 23294610
WHO South East Asia J Public Health. 2017 Apr;6(1):60-66
pubmed: 28597861
Psychoneuroendocrinology. 2006 Apr;31(3):347-54
pubmed: 16213663
J Affect Disord. 2021 May 1;286:351-359
pubmed: 33757648
Pharmacol Biochem Behav. 2015 Sep;136:107-16
pubmed: 26188166
J Affect Disord. 2012 Feb;136(3):1164-73
pubmed: 21782251
Metab Brain Dis. 2017 Jun;32(3):757-764
pubmed: 28197877
Int J Obes (Lond). 2007 Jul;31(7):1155-64
pubmed: 17264844
J Affect Disord. 2021 May 15;287:54-68
pubmed: 33773359
Neuroendocrinology. 2014;100(2-3):178-90
pubmed: 25300940
Pharmacol Biochem Behav. 2002 Mar;71(3):431-47
pubmed: 11830178
Diabet Med. 2008 Nov;25(11):1330-6
pubmed: 19046224
J Affect Disord. 2021 Nov 1;294:932-938
pubmed: 34375221
Pharm Res. 2013 Oct;30(10):2475-84
pubmed: 23135822
Psychosom Med. 2007 May;69(4):300-5
pubmed: 17470664
Psychother Psychosom. 2017;86(1):31-46
pubmed: 27884012
Sports Med. 2020 Feb;50(2):295-330
pubmed: 31552570
Diabetologia. 2008 Oct;51(10):1930-2
pubmed: 18663426
Ann Agric Environ Med. 2014;21(4):815-21
pubmed: 25528926
Psychoneuroendocrinology. 2017 Jul;81:113-121
pubmed: 28441588
Am J Psychiatry. 2018 Mar 1;175(3):225-231
pubmed: 29241357
Arch Gen Psychiatry. 2006 Jul;63(7):824-30
pubmed: 16818872
Diabetes Care. 2011 Jan;34(1):71-6
pubmed: 20929992
Diabetes Care. 2013 Sep;36(9):2551-8
pubmed: 23735726
Diabet Med. 2013 Jul;30(7):767-77
pubmed: 23711019